Ann: Accelerating Commercialisation with Largest US A&A Practice, page-17

some answers to some of @CM662 latest questions from ADR website----------

Adherium Ltd




ASX:ADR

25/08/2023


....................................
The difference is we are now seeing the benefits of our progress, such as being able to announce agreements such as the one with Allergy Partners. Allergy Partners is the largest asthma and allergy practice in the USA, not a one-doctor practice and this agreement is a testament to our technology, strategy, and our team.
-----------------------------
This is re-iterating one of our core pillars of using improved patient outcomes to establish Adherium’s platform value with hospital systems. We are focused on not only RPM revenue but also value-based, risk-share contracts to more rapidly generate scale.
.....................................................................

Yes, we are increasing headcount in the USA with the patient onboarding process and to assist our partner's efforts in rolling out our technology.

...............................

We state that the implementation plan will have an initial rollout to three US states this quarter and clarify this relates to the quarter ending on the 30th Sept 2023. It is then planned to continue the expansion to more locations later this calendar year.
.....................

It is to highlight that our focus is signing commercial agreements, working with partners to launch, and then working with them to get patients onboarded.

................................................

We will disclose segment information based on geography and revenue categories as part of our annual report.

...............................



This type of information will need to be approved through our disclosure committee and will be made ready when approved

.................

I do not know why people with gripes on HC are not asking their questions on the ADR Investor site!